| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9190260 | Epilepsy & Behavior | 2005 | 13 Pages |
Abstract
In conclusion, BI, which is a measure of the margin of safety and tolerability of drugs in combination and comprises anticonvulsant and neurotoxic measures, was favorable for only one combination (LCZ and ETS at a fixed ratio of 1:3) with a value of 1.39. In contrast, LCZ and CZP constitute an unfavorable combination (BIÂ =Â 0.61-1.01). The combinations of LCZ with PB or VPA do not offer any advantage as assessed by the parameters (BI range: 0.75-0.91) used in this study. However, these conclusions are confounded by the fact that LCZ is associated with significant pharmacokinetic interactions.
Keywords
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Jarogniew J. Luszczki, Neville Ratnaraj, Philip N. Patsalos, Stanislaw J. Czuczwar,
